GlassScriptPhysician profile
Ingrid Halvorson
NPI 1013336114
$2,154.98
in general payments reported to CMS, 2019-2025
25 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $119 · 2023: $410 · 2024: $618 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $271.05 | 2024 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $236.04 | 2021-2022 | |
| Tactile Systems Technology INC | $223.36 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Immunitybio, INC. | $147.00 | 2025 | |
| Merck Sharp & Dohme LLC | $142.69 | 2023-2024 | Keytruda |
| Sumitomo Pharma America, INC. | $109.52 | 2023 | Orgovyx |
| G1 Therapeutics, INC. | $108.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.91 | 2021 | |
| Janssen Biotech, INC. | $102.60 | 2024 | Tecvayli, Darzalex, Akeega |
| Puma Biotechnology, INC. | $97.64 | 2023 | |
| Incyte Corporation | $81.01 | 2021 | |
| Astellas Pharma US INC | $77.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $74.49 | 2024-2025 | Onglyza |
| Celgene Corporation | $70.37 | 2021 | |
| Janssen Scientific Affairs, LLC | $51.67 | 2025 | Erleada |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $46.63 | 2025 | Spaceoar System |
| Ge Healthcare | $29.03 | 2021 | |
| Novocure INC. | $28.80 | 2021 | |
| Genentech USA, INC. | $26.65 | 2025 | Itovebi |
| Tersera Therapeutics LLC | $26.06 | 2021 | |
| Teleflex LLC | $23.57 | 2025 | Urolift |
| Novartis Pharmaceuticals Corporation | $22.53 | 2024 | |
| Lilly USA, LLC | $21.42 | 2024 | Kisunla |
| Caris Mpi, INC. | $18.67 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Halvorson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.